EGFR and squamous cell carcinoma: The NCCN NSCLC Panel advocates for the testing of EGFR mutations and other biomarkers in patients diagnosed with metastatic non-squamous NSCLC or NSCLC NOS, as well as in cases of squamous cell carcinoma [21,22,23,24].